U.S. Stock Movement | Cytokinetics (CYTK.US) Surges Over 10% as Aficamten Receives Approval for Market Launch

Stock News12-22 23:50

On Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to hit a new annual high, currently trading at $69.34. The catalyst behind this rally is the recent approval by the National Medical Products Administration (NMPA) of Cytokinetics' Class 1 innovative drug Aficamten (brand name: Xinshuping) through a priority review process. The drug is indicated for treating adult patients with obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) functional class II-III, aiming to improve exercise capacity and symptoms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191261621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191261621","market":"fut","top_or_hot":-1,"title":"U.S. Stock Movement | Cytokinetics (CYTK.US) Surges Over 10% as Aficamten Receives Approval for Market Launch","media":"Stock News","content":"<p>On Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to hit a new annual high, currently trading at $69.34. The catalyst behind this rally is the recent approval by the National Medical Products Administration (NMPA) of Cytokinetics' Class 1 innovative drug Aficamten (brand name: Xinshuping) through a priority review process. The drug is indicated for treating adult patients with obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) functional class II-III, aiming to improve exercise capacity and symptoms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Movement | Cytokinetics (CYTK.US) Surges Over 10% as Aficamten Receives Approval for Market Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Movement | Cytokinetics (CYTK.US) Surges Over 10% as Aficamten Receives Approval for Market Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-22 23:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to hit a new annual high, currently trading at $69.34. The catalyst behind this rally is the recent approval by the National Medical Products Administration (NMPA) of Cytokinetics' Class 1 innovative drug Aficamten (brand name: Xinshuping) through a priority review process. The drug is indicated for treating adult patients with obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) functional class II-III, aiming to improve exercise capacity and symptoms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"","article_id":"1191261621","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191261621","pubTimestamp":1766418613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to hit a new annual high, currently trading at $69.34. The catalyst behind this rally is the recent approval by the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYTK":"Cytokinetics","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"美股动向|Aficamten获批上市，Cytokinetics(CYTK.US)大涨超10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTK":1},"content_text":"On Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to hit a new annual high, currently trading at $69.34. The catalyst behind this rally is the recent approval by the National Medical Products Administration (NMPA) of Cytokinetics' Class 1 innovative drug Aficamten (brand name: Xinshuping) through a priority review process. The drug is indicated for treating adult patients with obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) functional class II-III, aiming to improve exercise capacity and symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191261621","isCrawlerRequest":true}